A detailed history of Susquehanna International Group, LLP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 1,115,105 shares of VKTX stock, worth $58.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,115,105
Previous 1,404,715 20.62%
Holding current value
$58.6 Million
Previous $74.5 Million 5.19%
% of portfolio
0.01%
Previous 0.01%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$49.84 - $70.47 $14.4 Million - $20.4 Million
-289,610 Reduced 20.62%
1,115,105 $70.6 Million
Q2 2024

Aug 15, 2024

BUY
$47.39 - $80.2 $53 Million - $89.7 Million
1,118,798 Added 391.3%
1,404,715 $74.5 Million
Q1 2024

May 07, 2024

BUY
$17.4 - $94.5 $2.38 Million - $12.9 Million
136,635 Added 91.53%
285,917 $23.4 Million
Q4 2023

Feb 14, 2024

BUY
$9.24 - $19.64 $162,198 - $344,760
17,554 Added 13.33%
149,282 $2.78 Million
Q3 2023

Nov 14, 2023

BUY
$10.92 - $16.0 $360,873 - $528,752
33,047 Added 33.49%
131,728 $1.46 Million
Q2 2023

Aug 11, 2023

SELL
$14.84 - $24.79 $18.5 Million - $30.9 Million
-1,244,627 Reduced 92.65%
98,681 $1.6 Million
Q1 2023

May 16, 2023

BUY
$8.08 - $17.33 $4.22 Million - $9.05 Million
522,450 Added 63.65%
1,343,308 $22.4 Million
Q4 2022

Feb 14, 2023

BUY
$2.72 - $9.4 $942,803 - $3.26 Million
346,619 Added 73.09%
820,858 $7.72 Million
Q3 2022

Nov 14, 2022

BUY
$2.55 - $3.89 $832,427 - $1.27 Million
326,442 Added 220.87%
474,239 $1.29 Million
Q2 2022

Aug 15, 2022

SELL
$2.11 - $3.15 $158,328 - $236,366
-75,037 Reduced 33.67%
147,797 $427,000
Q1 2022

May 16, 2022

SELL
$3.0 - $4.88 $154,104 - $250,675
-51,368 Reduced 18.73%
222,834 $669,000
Q4 2021

Feb 14, 2022

BUY
$4.6 - $6.72 $379,210 - $553,976
82,437 Added 42.99%
274,202 $1.26 Million
Q3 2021

Nov 15, 2021

SELL
$5.58 - $7.04 $353,732 - $446,286
-63,393 Reduced 24.84%
191,765 $1.2 Million
Q2 2021

Aug 11, 2021

BUY
$5.19 - $6.73 $257,029 - $333,296
49,524 Added 24.08%
255,158 $1.53 Million
Q1 2021

May 17, 2021

SELL
$5.74 - $9.67 $412,246 - $694,499
-71,820 Reduced 25.89%
205,634 $1.3 Million
Q4 2020

Feb 16, 2021

SELL
$5.3 - $6.71 $233,295 - $295,360
-44,018 Reduced 13.69%
277,454 $1.56 Million
Q3 2020

Nov 16, 2020

BUY
$5.73 - $8.11 $302,950 - $428,783
52,871 Added 19.68%
321,472 $1.87 Million
Q2 2020

Aug 14, 2020

SELL
$4.35 - $8.08 $135,693 - $252,047
-31,194 Reduced 10.41%
268,601 $1.94 Million
Q1 2020

May 15, 2020

BUY
$3.45 - $7.95 $143,965 - $331,745
41,729 Added 16.17%
299,795 $1.4 Million
Q3 2019

Nov 14, 2019

BUY
$6.55 - $8.6 $618,313 - $811,831
94,399 Added 57.68%
258,066 $1.78 Million
Q2 2019

Aug 16, 2019

BUY
$7.67 - $10.63 $860,236 - $1.19 Million
112,156 Added 217.73%
163,667 $1.36 Million
Q2 2019

Aug 14, 2019

BUY
$7.67 - $10.63 $16,789 - $23,269
2,189 Added 4.44%
51,511 $427,000
Q4 2018

Feb 14, 2019

SELL
$7.16 - $16.21 $1.91 Million - $4.32 Million
-266,265 Reduced 84.37%
49,322 $377,000
Q1 2018

May 15, 2018

BUY
$4.11 - $6.93 $1.09 Million - $1.83 Million
264,340 Added 515.82%
315,587 $1.38 Million
Q3 2017

Nov 14, 2017

BUY
$0.94 - $1.91 $48,172 - $97,881
51,247
51,247 $98,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.03B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.